ANI Pharmaceuticals
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides i...
Latest News
10 days ago · seekingalpha.com
ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call TranscriptANI Pharmaceuticals, Inc. ( ANIP ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Irina Rivkind Koffler - Vice President of Investor Relations Nikhil Lalwani - President, CEO & Director Mary Pao - Chief Medical Officer Christopher Mutz - Senior Vp & Head of Rare Disease Stephen Carey - Senior VP of Finance & CFO Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Yuchen Ding - Jefferies LLC, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Gary Nachman - Canaccord Genuity Corp., Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. Third Quarter 2026 Earnings Results Conference Call.
12 days ago · marketbeat.com
ANI Pharmaceuticals Q3 Earnings Call HighlightsANI Pharmaceuticals NASDAQ: ANIP reported 28% revenue growth for the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value, while lowering its full-year sales outlook for Cortrophin Gel after pharmacy bottlenecks slowed the conversion of new patient cases into treatment.
12 days ago · zacks.com
ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to SayThe headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
12 days ago · zacks.com
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue EstimatesANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.7 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.04 per share a year ago.
12 days ago · globenewswire.com
ANI Pharmaceuticals Reports Third Quarter 2026 Financial ResultsPRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2026.
12 days ago · globenewswire.com
REPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease BusinessPRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).
12 days ago · globenewswire.com
ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease BusinessPRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announces a recommended public offer to acquire Egetis Therapeutics AB (publ) (“Egetis”) (the “Offer”).
14 days ago · globenewswire.com
ANI Pharmaceuticals to Present at Upcoming November Investor ConferencesPRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:
25 days ago · globenewswire.com
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ETPRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET.
29 days ago · globenewswire.com
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release CapsulesPRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI's Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta®.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ANIP